Business
Xilio Therapeutics Announces Initiation of Phase 2 Trial for Efarindodekin Alfa (XTX301), a Tumor-Activated IL-12, and Achievement of $17.5 Million Development Milestone Under Exclusive License Agreement with Gilead
Phase 1 data for efarindodekin alfa (XTX301) demonstrate promising anti-tumor activity in patients with advanced solid tumors Achievement of milestone extends anticipated cash runway into first quarter of 2027 WALTHAM, Mass., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced the initiation of patient dosing in Phase 2
About this update from Gilead Sciences, Inc.
[{"type":"image","alt":"Xilio Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Xilio Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":1280,"height":720,"url":"https://media.zenfs.com/en/globenewswire.com/4b2fe3809d51980d292c758894d943af"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/bVUqvk2mU.eS_7S2ewaMtA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTU0MDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/4b2fe3809d51980d292c758894d943af","width":960,"height":540},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/PXARsYz2QAy6fM85eGCsig--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD0xMzUwO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/4b2fe3809d51980d292c758894d943af","width":1200,"height":675}},"lazy":false},{"type":"text","content":"Phase 1 data for efarindodekin alfa (XTX301) demonstrate promising anti-tumor activity in patients with advanced solid tumors","length":125,"tagName":"p"},{"type":"text","content":"Achievement of milestone extends anticipated cash runway into first quarter of 2027","length":83,"tagName":"p"},{"type":"text","content":"WALTHAM, Mass., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced the initiation of patient dosing in Phase 2 of an ongoing Phase 1/2 clinical trial evaluating efarindodekin alfa (XTX301), a tumor-activated IL-12, as a monotherapy in patients with certain advanced solid tumors. In addition, today Xilio announced the achievement of a $17.5 million development milestone under Xilio’s license agreement with Gilead Sciences, Inc. (Gilead) and updated data from the ongoing Phase 1 trial for efarindodekin alfa.","length":695,"tagName":"p"},{"type":"text","content":"“We are pleased to announce the initiation of the Phase 2 clinical trial for efarindodekin alfa (XTX301), a tumor-activated IL-12, in patients with advanced solid tumors,” said René Russo, Pharm.D., president and chief executive officer of Xilio. “The achievement of this important milestone highlights the promising Phase 1 data demonstrated for efarindodekin alfa to date, including two partial responses in late-line patients with advanced solid tumors and a generally well-tolerated safety profile. These data also pro...